Duration of Diabetes and Incident Heart Failure: The ARIC (Atherosclerosis Risk In Communities) Study.
duration of disease
heart failure
outcomes
risk
type 2 diabetes
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
02
04
2021
revised:
08
06
2021
accepted:
09
06
2021
entrez:
30
7
2021
pubmed:
31
7
2021
medline:
29
10
2021
Statut:
ppublish
Résumé
This study assessed the association of diabetes duration with incident heart failure (HF). Diabetes increases HF risk. However, the independent effect of diabetes duration on incident HF is unknown. We included 9,734 participants (mean age 63 years, 58% women, 22% Black) at ARIC (Atherosclerosis Risk In Communities) Visit 4 (1996-1998) without HF or coronary heart disease. We calculated diabetes duration at Visit 4 (baseline), utilizing diabetes status at the first 4 ARIC visits spaced 3 years apart, and self-reported diagnosis date for those with diabetes diagnosed before Visit 1. We used Cox regression to estimate associations of diabetes duration with incident HF, accounting for intercurrent coronary heart disease and other risk factors. We performed analyses stratified by age (<65 years or ≥65 years), race, sex, and glycemic control (hemoglobin A Over 22.5 years of follow-up, there were 1,968 HF events. Compared to those without diabetes, HF risk rose with longer diabetes duration, with the highest risk among those with ≥15 y diabetes duration (HR: 2.82; 95% CI: 2.25-3.63). Each 5-year increase in diabetes duration was associated with a 17% (95% CI: 11-22) relative increase in HF risk. Similar results were observed across HF subtypes. The HF and diabetes duration associations were stronger among those aged <65 years, those with HbA Delaying diabetes onset may augment HF prevention efforts, and therapies to improve HF outcomes might target those with long diabetes duration.
Sections du résumé
OBJECTIVES
This study assessed the association of diabetes duration with incident heart failure (HF).
BACKGROUND
Diabetes increases HF risk. However, the independent effect of diabetes duration on incident HF is unknown.
METHODS
We included 9,734 participants (mean age 63 years, 58% women, 22% Black) at ARIC (Atherosclerosis Risk In Communities) Visit 4 (1996-1998) without HF or coronary heart disease. We calculated diabetes duration at Visit 4 (baseline), utilizing diabetes status at the first 4 ARIC visits spaced 3 years apart, and self-reported diagnosis date for those with diabetes diagnosed before Visit 1. We used Cox regression to estimate associations of diabetes duration with incident HF, accounting for intercurrent coronary heart disease and other risk factors. We performed analyses stratified by age (<65 years or ≥65 years), race, sex, and glycemic control (hemoglobin A
RESULTS
Over 22.5 years of follow-up, there were 1,968 HF events. Compared to those without diabetes, HF risk rose with longer diabetes duration, with the highest risk among those with ≥15 y diabetes duration (HR: 2.82; 95% CI: 2.25-3.63). Each 5-year increase in diabetes duration was associated with a 17% (95% CI: 11-22) relative increase in HF risk. Similar results were observed across HF subtypes. The HF and diabetes duration associations were stronger among those aged <65 years, those with HbA
CONCLUSIONS
Delaying diabetes onset may augment HF prevention efforts, and therapies to improve HF outcomes might target those with long diabetes duration.
Identifiants
pubmed: 34325890
pii: S2213-1779(21)00282-1
doi: 10.1016/j.jchf.2021.06.005
pmc: PMC8629143
mid: NIHMS1721050
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
594-603Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL152440
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK089174
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007024
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146907
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL153774
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005I
Pays : United States
Informations de copyright
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures The ARIC study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), and Department of Health and Human Services, under Contract nos. HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, and HHSN268201700004I. The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Tcheugui was supported by National Institutes of Health (NIH)/NHLBI grant K23 HL153774. Dr Hamo was supported by NIH/NHLBI grant number T32 HL007024. Dr Selvin was supported by NIH/National Institute of Diabetes and Digestive and Kidney Diseases grants K24 HL152440 and R01DK089174, and American Heart Association grant 20SFRN35120152. Dr Ndumele was supported by NIH grant R01HL146907 and American Heart Association grant 20SFRN35120152. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Am J Epidemiol. 1989 Apr;129(4):687-702
pubmed: 2646917
Diabetologia. 2014 Apr;57(4):660-71
pubmed: 24477973
Diabetes Care. 2004 Mar;27(3):704-8
pubmed: 14988289
Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1081-1091
pubmed: 30318112
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
Clin Chem. 2012 Dec;58(12):1648-55
pubmed: 23019309
BMJ. 1997 Mar 15;314(7083):783-8
pubmed: 9080995
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Am J Cardiol. 2008 Apr 1;101(7):1016-22
pubmed: 18359324
Diabetes Res Clin Pract. 2015 Apr;108(1):55-66
pubmed: 25686509
Diabetologia. 2008 Dec;51(12):2197-204
pubmed: 18828004
Diabetes Care. 1992 Jul;15(7):815-9
pubmed: 1516497
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Clin Sci (Lond). 2001 Dec;101(6):671-9
pubmed: 11724655
JAMA. 2001 Jul 25;286(4):421-6
pubmed: 11466120
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
JAMA. 2015 Sep 8;314(10):1021-9
pubmed: 26348752
Diabetologia. 2014 Dec;57(12):2465-74
pubmed: 25226881
Circ Heart Fail. 2012 Mar 1;5(2):152-9
pubmed: 22271752
Am J Epidemiol. 1993 Jun 15;137(12):1328-40
pubmed: 8333414
Lancet. 2020 Sep 19;396(10254):819-829
pubmed: 32877652
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Stroke. 2002 Jul;33(7):1776-81
pubmed: 12105351
N Engl J Med. 2009 Mar 19;360(12):1179-90
pubmed: 19297571
Arch Intern Med. 2008 Oct 27;168(19):2138-45
pubmed: 18955644
Diabetes Obes Metab. 2021 Jun;23(6):1361-1370
pubmed: 33620747
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Diabetes Care. 2018 Apr;41(4):731-738
pubmed: 29317451
Diabetologia. 2019 Sep;62(9):1550-1560
pubmed: 31317230
Arch Intern Med. 2001 Jul 23;161(14):1717-23
pubmed: 11485504
Stroke. 2012 May;43(5):1212-7
pubmed: 22382158